Results of Tabula Rasa HealthCare’s First Simulated Clinical Study on Proposed COVID-19 Treatments and Therapies is Published
MOORESTOWN, NJ, (August 12, 2020) – Tabula Rasa HealthCare, Inc® (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announces TRHC’s Precision Pharmacotherapy Research and Development Institute (PPRDI) published the research article, “Risk of Adverse Drug Events Following the Virtual Addition of COVID-19 Repurposed Drugs to Drug Regimens of Frail Older Adults with Polypharmacy”, in the August 10, 2020, online edition of the Journal of Clinical Medicine. The article is... Read More
Regence and TRHC Partner on COVID-19 Virtual Clinical Trial to Assess Proposed Treatment Risks
Moorestown, NJ, June 9, 2020 – Regence and Tabula Rasa HealthCare® (NASDAQ: TRHC) announced today that the companies have partnered on a virtual clinical trial to assess the risk of adverse drug events (ADEs) associated with drugs repurposed for the treatment of COVID-19. The trial examines de-identified medical information for approximately 500,000 Regence health plan members across multiple lines of business. Regence is a family of health plans in Oregon, Idaho, Utah and select counties... Read More
TRHC Fills the Information Gap on COVID-19 Proposed Therapies with a New Digital Resource
Moorestown, NJ, May 19, 2020 – Tabula Rasa HealthCare® Corporation (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today published on the web the TRHC COVID-19 Treatment and Therapy Digital Resource. Developed by TRHC’s Precision Pharmacotherapy Research & Development Institute, the resource provides a comprehensive analysis and clinical reviews of potential treatments and therapies for COVID-19. “There are knowledge gaps surrounding the proposed treatments for COVID-19,” said TRHC Chairman and CEO... Read More
TRHC Launches First Large Simulation Study to Assess Adverse Drug Events with proposed COVID-19 Treatments
Moorestown, NJ, April 29, 2020 – Tabula Rasa HealthCare Corporation® (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, announced today it is running a clinical study assessing the risk of adverse drug events (ADEs) associated with drugs repurposed for the treatment of COVID-19 in older adults on multiple medications. “This study showcases the depth and breadth of our clinical research capabilities,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “The... Read More
Tabula Rasa HealthCare and Strategic Solutions Network Partner on a Free COVID-19 Medication Safety Webinar
MOORESTOWN, N.J., April 23, 2020 (GLOBE NEWSWIRE) — Tabula Rasa HealthCare Corporation® (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, and Strategic Solutions Network, a privately-held business-to-business conference company, will present a free webinar entitled Important Medication Safety Considerations for COVID-19 Treatment on Thursday, May 7, 2020 at 1 p.m. EDT. Participants may register here. The webinar will discuss the importance of understanding the risks associated with COVID-19 treatment risks, particularly... Read More